Background JTE-052 is a novel Janus kinase inhibitor presently under clinical development for the topical treatment of atopic dermatitis (AD). Objectives To evaluate the efficacy and safety of JTE-052 ointment in Japanese adult patients with AD. Methods Patients with moderate-to-severe AD were randomized (2: 2: 2: 2: 1: 1) to receive JTE-052 ointment at 0Á25%, 0Á5%, 1% or 3%, the vehicle ointment or tacrolimus 0Á1% ointment (reference) twice daily for 4 weeks. The primary efficacy end point was the percentage change in modified Eczema Area Severity Index (mEASI) score from baseline at the end of treatment (EOT). Secondary efficacy end points included change from baseline in the pruritus numerical rating scale (NRS) score. Results In total, 327 patients were enrolled. At EOT, the least-squares mean percentage changes from baseline in mEASI score for JTE-052 at 0Á25%, 0Á5%, 1% and 3% and the vehicle ointment were À41Á7%, À57Á1%, À54Á9%, À72Á9% and À12Á2%, respectively. All JTE-052 groups showed significant reductions of mEASI score vs. the vehicle group (P < 0Á001 for all). In the tacrolimus group, the mean percentage change in mEASI score was À62Á0%. The JTE-052 groups also showed significant improvement in other parameters; notably, the pruritus NRS score was reduced as early as day 1 night-time. JTE-052 ointment at doses up to 3% was safe and well tolerated. Conclusions Topical JTE-052 markedly and rapidly improved clinical signs and symptoms in Japanese adult patients with moderate-to-severe AD, with a favourable safety profile. The study results indicate that topical JTE-052 is a promising therapeutic option for AD. The trial registration number is JapicCTI-152887.
• The study results indicate that topical JTE-052 is a promising therapeutic option for AD.
Atopic dermatitis (AD) is a chronic relapsing eczematous skin disease characterized by pruritus and inflammation accompanied by cutaneous dysfunction such as dry and barrier-disrupted skin. 1 The worldwide prevalence of AD is estimated to be 15-30% in children and 2-10% in adults. 2 The principal goal of treatment of AD is to reach and maintain a state of absent or minor clinical symptoms that do not disrupt the patient's daily activities, requiring as little pharmacotherapy as possible. 1 Topical corticosteroids and tacrolimus ointment (the only topical calcineurin inhibitor available in Japan) form the mainstay of controlling skin inflammation in AD. However, these drugs have some limitations. Long-term use of topical corticosteroids is known to be associated with cutaneous adverse reactions such as atrophy and teleangiectasia. 1 Concerning treatment with tacrolimus ointment, irritation symptoms at the application site, such as a burning sensation and hot flushes, often appear, especially during the early phase of treatment, and a possible increased risk of local skin infections should be considered. 3 The anti-inflammatory effect of these drugs is well known, whereas sufficient evidence of improvement of the disrupted skin barrier function and pruritus has not been established. Although the pathogenesis of AD is multifactorial, immunological abnormalities, skin barrier dysfunction and pruritus are well known to be major factors involved in the pathogenesis and progression. 4 Immunological abnormalities include the abnormal production of cytokines such as interleukin (IL)-4, IL-5, IL-12, IL-13, interferon-c, thymic stromal lymphopoietin (TSLP) and granulocyte-macrophage colony-stimulating factor. [5] [6] [7] Skin barrier dysfunction is believed to be due mainly to filaggrin gene mutations, 8, 9 and the overexpression of IL-4
and IL-13 is associated with a reduction in filaggrin production. 10 Pruritus has been shown to be induced by IL-31. 11, 12 Various cytokines exert their biological effects via the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway, and several JAK inhibitors are approved or under development for the treatment of cytokine-mediated diseases.
13 JTE-052 is a novel JAK inhibitor developed by Japan Tobacco Inc. (also in development for dermatological conditions by LEO Pharma, code LEO124249). JTE-052 has been shown to inhibit the JAK1, JAK2, JAK3 and tyrosine kinase 2 enzymes in enzymatic assays. 14 JTE-052 has also been shown to inhibit the activation of inflammatory cells such as T cells, B cells, monocytes and mast cells in vitro, 14 and to suppress skin inflammation in animal dermatitis models. 15 Additionally, JTE-052 improves the skin barrier dysfunction by promoting the production of keratinocyte proteins including filaggrin, 16 and suppresses pruritus induced by IL-31. 17 Consequently, topical JTE-052 is expected to be a novel drug for the treatment of AD, suppressing inflammation and pruritus, as well as restoring skin barrier function. Indeed, tofacitinib ointment, another JAK inhibitor, has demonstrated favourable efficacy in a phase IIa study of patients with AD. 18 In a phase I clinical study, JTE-052 ointment was found to be efficacious and safe in patients with AD when administered at doses up to 3% for 1 week (unpublished data). In the present phase II study, we evaluated the efficacy and safety of JTE-052 ointment in Japanese adult patients with moderateto-severe AD over a 4-week period.
Patients and methods

Study design
This study was conducted at 38 medical institutions in Japan. The study information is registered with JAPIC Clinical Trials Information (www.clinicaltrials.jp), number JapicCTI-152887.
This was a phase II, randomized, vehicle-controlled, intergroup comparison study, comprising six treatment groups: four JTE-052 groups, one vehicle group and one tacrolimus group. This study was not under double-blind conditions in the JTE-052 and vehicle groups because the appearance of each strength of the JTE-052 ointments and vehicle ointment was different. However, to keep the investigators and patients blinded concerning the study treatment, the following methods were performed: the designated site personnel other than the investigators dispensed the study drugs and collected them from patients, and neither investigators nor patients were informed about the appearance of the ointments. The tacrolimus group was under open-label conditions; neither investigators nor patients were blinded concerning the study treatment, as this group was included in the study as a reference group for exploratory comparison with the JTE-052 groups.
After a screening period of approximately 4 weeks, patients were randomized (2: 2: 2: 2: 1: 1) to receive JTE-052 ointment at 0Á25%, 0Á5%, 1% or 3%, the vehicle ointment or tacrolimus 0Á1% ointment for 4 weeks ( Fig. S1 ; see Supporting Information). A computer-generated randomization scheme was performed based on a permuted block method. An appropriate amount of each ointment was applied twice daily to the areas affected by eczema with inflammation, depending on the size of the affected area; however, the scalp, palms and soles, as well as dry skin areas, were excluded. The maximum dose per application was limited to 5 g. Rescue medication could be used for the treatment of worsening of AD according to the investigator's judgement and was limited to prednisolone valerate acetate 0Á3%. The patients who used the rescue medication could continue the study; however, concomitant application of the study treatment and rescue medication to the same area was prohibited.
This study was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. Studyrelated documents were approved by the institutional review boards, and all patients provided written informed consent before study initiation.
Study population
We enrolled Japanese patients aged 16-65 years with moderate-to-severe AD. The diagnosis of AD was made according to the criteria of the Japanese Dermatological Association, 1 and the severity classification was based on the measures of severity by the research group granted by the Ministry of Health, Labour and Welfare. 19 At screening and baseline, eligible patients had to have a modified Eczema Area Severity Index (mEASI) score ≥ 10 (the mEASI score was calculated by excluding the head/neck region score from the EASI 20 total score); an Investigator's Global Assessment (IGA) score of 3 (moderate) or higher; and eczema with inflammation, affecting 10-30% of the body surface area (BSA). A summary of the exclusion criteria is provided in File S1 (see Supporting Information).
Assessments
The primary efficacy end point was the percentage change in mEASI score from baseline at the end of treatment (EOT). For the mEASI score, the percentage change at each time point and the proportions of patients achieving ≥ 50%, ≥ 75% or ≥ 90% improvement from baseline (mEASI-50, 75, 90 response rates) were also assessed as secondary efficacy end points.
Other secondary efficacy end points included changes or percentage changes from baseline at EOT and each time point in the EASI score, IGA score, face/neck IGA score, pruritus NRS score (including daily changes) and percentage BSA affected by AD. In addition, the proportion of patients with an IGA score of 0 or 1, and achieving ≥ 2-point improvement from baseline at EOT was assessed. A detailed description of the parameters is provided in File S1 and Table S1 (see Supporting  Information) . Safety parameters included symptoms, objective findings, vital signs and laboratory tests. Verbatim terms of adverse events (AEs) reported by the investigators were coded using the Medical Dictionary for Regulatory Activities version 18Á0.
Blood samples were collected at week 2 and week 4 to measure plasma concentrations of JTE-052. The lower limit of quantification was 1Á00 ng mL À1 .
Sample size
The sample-size calculation was based on the results of a phase I study of JTE-052 ointment in patients with AD (JapicCTI-142494, unpublished data). The sample size was estimated to be 60 for each JTE-052 group and 30 for the vehicle group, under the conditions of an assignment ratio of 2 : 1, to detect a significant difference between the groups in the percentage change from baseline in the EASI score with the t-test (5% significance level, 90% power). For the tacrolimus group, the target sample size was 30, given the nature of the group for exploratory comparisons.
Statistical evaluation
Primary analyses of efficacy, safety and pharmacokinetics were performed on the population that comprised patients who had undergone the respective study-specified assessments at least once after the start of study treatment.
The baseline value for efficacy parameters was defined as the measured value on the day of the start of study treatment (day 1), except for the pruritus NRS score, the baseline value of which was the mean value of the past week before the start of study treatment. The EOT value for efficacy parameters was defined as the value at week 4 or study discontinuation. For patients receiving rescue medication, the values obtained after the use of rescue medication were excluded from all of the efficacy analyses, and the EOT value was defined as the last value immediately before the use of rescue medication. For patient demographics and baseline values of efficacy assessments, imbalances between treatment groups were assessed at a two-sided significance level of roughly 15%.
Efficacy parameters were analysed using ANCOVA with the relevant baseline value as the covariate. The least-squares mean change or percentage change from baseline was calculated. The difference between each JTE-052 group and the vehicle group was assessed at EOT and each time point. Odds ratios were calculated for responder analyses of mEASI and IGA scores. The statistical tests of efficacy assessments were two sided at the 5% significance level. No statistical comparisons of the JTE-052 groups with the tacrolimus group were performed.
Results
Patients
Of the 366 patients providing written informed consent, 327 received study treatment (Fig. 1) . Overall, 309 patients completed the study and 18 patients discontinued prematurely. The vehicle group showed the highest rate of use of rescue medication among the treatment groups (13 patients, 41%); the use rate of rescue medication in the JTE-052 groups appeared to decrease dose dependently, with 10% (n = 7) for JTE-052 at 0Á25%, 6% (n = 4) for JTE-052 at 0Á5%, 2% (n = 1) for JTE-052 at 1%, and 3% (n = 2) for JTE-052 at 3%. The rate in the tacrolimus group was 7% (n = 2).
Concerning patient demographics, a difference between treatment groups was noted in the mean duration of AD; however, the difference was not considered to be relevant in the study assessments (Table 1 ). There were no statistically differences in the other baseline patient demographics for efficacy assessments among the treatment groups (Table S2 ; see Supporting Information). Of note, one patient in the vehicle group was excluded from efficacy analyses because the patient never had efficacy data after the start of study treatment. The mean age was 30Á8 years, more than half of the patients were male (64Á4%), and most patients had moderate AD (87Á7%).
Efficacy
At EOT, all JTE-052 groups showed significant reductions of mEASI score from baseline vs. the vehicle group (P < 0Á001 for JTE-052 at all concentrations; Table S2 ; see Supporting Information). The least-squares mean percentage changes from baseline in mEASI score were À12Á2% for vehicle, À41Á7% for JTE-052 at 0Á25%, À57Á1% for JTE-052 at 0Á5%, À54Á9% for JTE-052 at 1% and À72Á9% for JTE-052 at 3%. The reductions in mEASI score appeared to be dose dependent in the JTE-052 groups. In the tacrolimus group, the mean percentage change in mEASI score at EOT was À62Á0%. In addition, all JTE-052 groups showed significantly greater reductions in mEASI score than the vehicle group from week 1 through week 4, except for JTE-052 at 0Á25% at week 3 ( Fig. 2 ; Table S3 ; see Supporting Information) and higher response rates (mEASI-50, 75 and 90) than the vehicle group at EOT (Table S4; see Supporting Information) .
At EOT, the JTE-052 groups at 0Á5%, 1% and 3% showed significant improvement from baseline vs. the vehicle group in the other parameters including the EASI score, IGA score, face/neck IGA score, pruritus NRS score and percentage BSA affected by AD. The JTE-052, 0Á25% group showed significant improvement in these efficacy parameters except for the IGA score and the face/neck IGA score. The tacrolimus group also showed a tendency of improvement in these efficacy parameters (Table S2 ; see Supporting Information).
For the pruritus NRS score as assessed twice daily by the patients, all JTE-052 groups and the tacrolimus group showed a tendency for decrease in the weekly mean score over the treatment period (Fig. 3a, b) . Significant reductions from baseline in both daytime and night-time NRS scores were noted at week 1 in the JTE-052 groups at 0Á5%, 1% and 3% (P < 0Á001 for each vs. vehicle). Analysis of the pruritus NRS scores over the first week of study treatment revealed the rapid improvement of pruritus from day 1 night-time in the JTE-052 0Á5%, 1% and 3% groups (P < 0Á001 for each vs. vehicle, Fig. 3c ). Similarly, there was a tendency of improvement in the other efficacy parameters in all JTE-052 groups over time (data not shown).
The proportion of patients with an IGA score of 0 (clear) or 1 (almost clear) and achieving ≥ 2-point improvement from baseline at EOT was significantly higher (P = 0Á039) in the JTE-052, 3% group (23%) than in the vehicle group (3%) ( Table S5 ; see Supporting Information). A representative photograph of a patient treated with JTE-052 at 3% shows symptomatic improvement ( Fig. S2 ; see Supporting Information). 
Safety and tolerability
Overall, AEs were reported in five of 32 (16%) patients in the vehicle group, 51 of 265 (19Á2%) in all JTE-052 groups, and 13 of 30 (43%) in the tacrolimus group (Table 2) . Among the 265 patients treated with JTE-052, the most common AE was nasopharyngitis (n = 9, 3Á4%), and no other AEs occurring in ≥ 2% of patients in the JTE-052 groups were noted (Table S6 ; see Supporting Information). Skin infections at the application site of study treatment occurred at a low frequency: furuncle (n = 3, 1Á1%), application-site acne (n = 3, 1Á1%), Kaposi varicelliform eruption (KVE) (n = 3, 1Á1%), acne (n = 1, 0Á4%), application-site folliculitis (n = 1, 0Á4%), erysipelas (n = 1, 0Á4%) and herpes simplex (n = 1, 0Á4%). In the tacrolimus group, AEs that occurred in at least two patients were application-site pain (n = 3, 10%) and application-site irritation (n = 2, 7%).
All AEs were considered mild or moderate in severity, and the majority were mild. Neither severe AEs nor serious AEs including death were reported during the study. AEs leading to study discontinuation were reported in four patients: contact dermatitis (JTE-052 at 0Á25%, n = 1), application-site irritation (JTE-052 at 0Á5%, n = 1 and tacrolimus, n = 1) and KVE (JTE-052 at 1%, n = 1). All of these events occurred at the application site of study treatment and resolved after study discontinuation. Except for KVE, all events were considered to be related to the study treatment by the investigators. The onset of KVE was found not at an application site of study treatment and thereafter the eruption spread to the application site because of increased susceptibility to infection in AD. Therefore, the event was considered to be unrelated to study treatment by the investigator.
No clinically significant changes in laboratory parameters or vital signs over time were noted in any of the treatment groups.
Pharmacokinetics
At week 2, the plasma concentrations of JTE-052 were low across the JTE-052 groups based on the median concentrations. The proportion of patients with detectable JTE-052 plasma concentrations appeared to be higher in the groups with JTE-052 at 1% (23%, n = 15) and 3% (52%, n = 33) than in the groups of JTE-052 at 0Á25% (10%, n = 7) and 0Á5% (6%, n = 4). A similar trend was noted at week 4 (Table S7 ; see Supporting Information).
Discussion
In this study, we demonstrated that topical JTE-052, a JAK inhibitor, markedly and rapidly improved clinical signs and symptoms in Japanese adult patients with moderate-to-severe AD.
All doses of JTE-052 ointment, ranging from 0Á25% to 3%, had greater efficacy than vehicle in all efficacy parameters, including the mEASI, EASI, IGA and pruritus NRS (61) 48 (70) 39 (60) 48 (73) 42 (65) 14 ( 21 (30) 26 (40) 18 (27) 23 (35) 16 (53) 116 (35Á6)
Duration of atopic dermatitis (years)
Severity of atopic dermatitis Moderate 26 (84) 61 (88) 61 (94) 56 (85) 56 (86) 26 ( (16) 8 (12) 4 (6) 10 (15) 9 (14) 4 (13) 40 ( scores, and percentage BSA affected by AD. Tofacitinib ointment, another JAK inhibitor, also showed favourable efficacy in patients with mild-to-moderate AD. 18 Therefore, our findings support the concept that inhibition of the JAK-STAT pathway is a potential therapeutic option for AD. JTE-052 has been shown to inhibit all the types of JAK enzymes (JAK1, JAK2, JAK3 and tyrosine kinase 2). 14 In AD, JAK1, JAK2 and JAK3 are overexpressed, and various JAK-related cytokines such as IL-4, IL-5, IL-13, IL-31 and TSLP play important roles in the pathophysiology of AD. 13, 21, 22 Additionally, the efficacy of JAK inhibitors seen in patients with AD may be attributed to the improving effect on skin barrier dysfunction, as well as the anti-inflammatory effect, given the involvement of IL-4 and IL-13 in keratinocyte differentiation, 10 and the promoting effect of JTE-052 on the production of keratinocyte proteins such as filaggrin. 16 One of the notable efficacy results in this study was the rapid antipruritic effect of JTE-052, with significant reductions in the pruritus NRS score noted from the night of study treatment initiation with JTE-052 at 0Á5% and higher doses. Pruritus can be induced by upregulation of IL-31, 11, 12 whose signalling is suppressed by inhibition of the JAK-STAT pathway. Therefore, the rapid antipruritic effect could be explained by the mechanism of action of JTE-052. 17 Oral and topical tofacitinib has also shown the benefit of JAK inhibitors on pruritus in both patients with AD and patients with psoriasis. 18, [22] [23] [24] [25] Pruritus is a distressing symptom in patients with AD and can lead to impairment of quality of life through sleep disturbance, as well as an increased risk of secondary infection and further exacerbation of AD due to scratching. 26 Therefore, the antipruritic effect of JAK inhibitors is considered a favourable factor in a new treatment for AD. Topical treatment with JTE-052 at doses up to 3% for 4 weeks was safe and well tolerated in patients with AD. The majority of AEs reported in the JTE-052 groups were mild in severity. No apparent differences between the JTE-052 and vehicle groups were noted in the incidence of AEs. No apparent dose-related AEs were noted either. Existing topical corticosteroids or tacrolimus can occasionally cause local skin infections. 1, 3 AEs associated with skin infections at the application site of JTE-052 included furuncles, acne and KVE, the incidences of which were very low in this study. Nonetheless, as JTE-052 has immunosuppressive activity, appropriate monitoring of local skin infections is necessary in future clinical studies of JTE-052. Tacrolimus ointment is associated with a high incidence of application-site reactions such as a burning sensation and application-site warmth, irritation and pain, especially in the early phase of treatment. 3 Fewer such symptoms were seen in the JTE-052 groups in this study. It is of note that the tacrolimus group in this study did not show a high incidence of these events, which may be due to the small sample size of the group or to the fact that many of the enrolled patients had been notified of application-site reactions by the investigators. In a phase I clinical study of an oral formulation of JTE-052, multiple administration of JTE-052 for 14 days was safe and tolerable at doses up to 50 mg per day. The mean maximum concentration was 436 ng mL À1 and the mean area under the concentration-time curve during the dosing interval was 1756 ng h mL À1 at the dose of 50 mg once daily (unpublished data). Compared with the exposure to JTE-052 by oral administration, that in the dermal application in the present study was found to be obviously low, although the proportions of patients with detectable JTE-052 plasma concentrations were greater for the 1% and 3% doses than for the lower doses. The distribution of patients by JTE-052 plasma concentration indicates that systemic exposure to JTE-052 was comparable between week 2 and week 4 during the 4-week treatment. The low systemic exposure may contribute to the lack of serious systemic infection such as opportunistic infections due to excessive immunosuppression in this study. Our study included an active comparator, tacrolimus 0Á1% ointment, to investigate the clinical effectiveness of JTE-052 ointment. Neither investigators nor patients were blinded concerning the study treatment in the tacrolimus group because this group was included as a reference group for explorative purposes and no statistical comparisons between tacrolimus and JTE-052 were performed. Therefore, the discussion on the differences between JTE-052 and tacrolimus is limited. Another study limitation is that the use of rescue medication was allowed for the treatment of worsening of AD, and the values obtained after the use of rescue medication were excluded from all of the efficacy analyses.
The results of this study should not be directly compared with those of other existing drugs for the treatment of AD because of the short study period and small sample size. We need to conduct further clinical studies of JTE-052 ointment to confirm the results of this study and to investigate the long-term safety in patients with AD. Clinical evaluation in paediatric patients should also be considered given the higher prevalence of AD in this population. In conclusion, our study demonstrates that topical JTE-052 has marked efficacy with rapid onset in the treatment of moderate-to-severe AD, as well as a favourable safety profile. The study results also support inhibition of the JAK-STAT pathway as a promising therapeutic option in patients with AD. Future studies of topical JTE-052 will make our findings in this study more robust. Data are displayed as the number of patients (%).
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Additional Supporting Information may be found in the online version of this article at the publisher's website: File S1 Summary of the exclusion criteria, parameters for efficacy assessments and principal investigators. Table S4 Proportion of patients achieving ≥ 50%, ≥ 75% or ≥ 90% improvement in modified Eczema Area Severity Index score at the end of treatment.
Table S5 Proportion of patients with an Investigator's Global Assessment score of 0 or 1, and achieving ≥ 2-point improvement from baseline at the end of treatment.
Table S6 Adverse events occurring in at least two patients in any of the treatment groups by preferred term. 
